Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function
/in Dendritic Cells, International Publications /von 2003-09-01 / J. Immunol. 2003 Sep;171(5):2366-73The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications /von 2003-08-01 / J. Neurooncol. 2003 Aug-Sep;64(1-2):161-76Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients
/in Cervical Cancer, Dendritic Cells, International Publications /von 2003-07-30 / J. Cancer Res. Clin. Oncol. 2003 Sep;129(9):521-30In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-06-15 / J. Surg. Res. 2003 Jun;112(2):189-97Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2003-05-01 / Trends Endocrinol. Metab. 2003 May-Jun;14(4):156-62Dendritic cell-based immunotherapy for the treatment of hematological malignancies
/in Acute Leukemia, Dendritic Cells, International Publications, Multiple Myeloma /von 2003-04-01 / Hematology 2003 Apr;8(2):97-104Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-6Fusions of breast cancer and dendritic cells as a novel cancer vaccine
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-63HER2 dendritic cell vaccines
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-72IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de